Table 2. Summary of SRP case series studies in radio-recurrent prostate cancer.
| Study | Study design | Number of patients | Median follow-up duration (months) | Pathologic organ confined disease (%) | PSM (%) | Lymph-node involvement (%) | BCR-free survival (%) | MFS (%) | CSS (%) | OS (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Chade et al., 2011 (28) | Multi-center, retrospective | 404 | 52.8 | 55 | 25 | 16 | 37 (10-yr) | 77 (10-yr) | 83 (10-yr) | NR |
| Marra et al., 2021 (29) | Multi-center, retrospective | 414 | 36 | 47.1 | 29.7 | 16 | 56.7 (5-yr) | NR | 97.7 (5-yr) | 92.1 (5-yr) |
| Calleris et al., 2023 (30) | Multi-center, retrospective | 1,030 (221: EAU fully met/809: EAU not-met) | 34 | 57.5/36.2 | 85.7/67.4 | 10.9/22.1 | 55/38 (5-yr) | 90/76 (5-yr) | NR | 89/84 (5-yr) |
SRP, salvage radical prostatectomy; PSM, positive surgical margin; BCR, biochemical recurrence; MFS, metastasis-free survival; CSS, cancer-specific survival; OS, overall survival; yr, year; NR, not reported; EAU, European Association of Urology.